What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trialsnews2024-10-23T14:19:56+00:00October 23rd, 2024|The New York Times|
El ‘médico rural’ que transformó nuestra manera de ver la demencianews2024-09-14T09:03:22+00:00September 14th, 2024|The New York Times|
Francisco Lopera, the ‘Country Doctor’ Who Upended Our Understanding of Dementianews2024-09-11T14:07:34+00:00September 11th, 2024|The New York Times|
Study Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’snews2024-05-06T16:19:15+00:00May 6th, 2024|The New York Times|
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Mostnews2023-12-08T22:46:17+00:00December 8th, 2023|The New York Times|
Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approvalnews2023-11-16T22:23:56+00:00November 16th, 2023|The New York Times|
A New Sickle Cell Treatment Will Change Lives — but How Many?news2023-10-30T09:01:12+00:00October 30th, 2023|The New York Times|
FDA Approves Biogen’s Drug for Rare Form of ALSnews2023-04-25T17:53:59+00:00April 25th, 2023|The New York Times|
A Dilemma for Governments: How to Pay for Million-Dollar Therapiesnews2023-01-25T00:27:17+00:00January 25th, 2023|The New York Times|
They Created a Drug for Susannah. What About Millions of Other Patients?news2022-12-19T22:40:09+00:00December 19th, 2022|The New York Times|
